The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?

作者信息

Palau Vanesa, Riera Marta, Soler Maria José

机构信息

Departamento de Nefrología, Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, REDINREN, Barcelona, España.

出版信息

Endocrinol Diabetes Nutr. 2017 May;64(5):237-240. doi: 10.1016/j.endinu.2017.03.006. Epub 2017 Apr 26.

DOI:10.1016/j.endinu.2017.03.006

PMID:28495318

Abstract

摘要

相似文献

The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?

Endocrinol Diabetes Nutr. 2017 May;64(5):237-240. doi: 10.1016/j.endinu.2017.03.006. Epub 2017 Apr 26.

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):435-437. doi: 10.1016/S2213-8587(17)30314-5. Epub 2017 Oct 10.

Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.

Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8.

Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus.

J Diabetes Complications. 2023 Dec;37(12):108630. doi: 10.1016/j.jdiacomp.2023.108630. Epub 2023 Oct 23.

EMPA-REG OUTCOME: The Nephrologist's Point of View.

Am J Cardiol. 2017 Jul 1;120(1S):S59-S67. doi: 10.1016/j.amjcard.2017.05.012. Epub 2017 May 30.

EMPA-REG OUTCOME: The Nephrologist's Point of View.

Am J Med. 2017 Jun;130(6S):S63-S72. doi: 10.1016/j.amjmed.2017.04.007. Epub 2017 May 16.

Introduction.

Am J Cardiol. 2017 Jul 1;120(1S):S1-S3. doi: 10.1016/j.amjcard.2017.05.008. Epub 2017 May 30.

Results from Cardiovascular Outcome Trials in Diabetes.

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].

MMW Fortschr Med. 2015 Oct 22;157(18):86-7.

引用本文的文献

Type 2 diabetes mellitus: Isn't it time to update the terminology?

World J Diabetes. 2025 Sep 15;16(9):107517. doi: 10.4239/wjd.v16.i9.107517.

Diabetes in spotlight: current knowledge and perspectives of photobiomodulation utilization.

Front Endocrinol (Lausanne). 2024 Mar 19;15:1303638. doi: 10.3389/fendo.2024.1303638. eCollection 2024.

Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.

touchREV Endocrinol. 2021 Nov;17(2):92-101. doi: 10.17925/EE.2021.17.2.92. Epub 2021 Nov 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?

Endocrinol Diabetes Nutr. 2017 May;64(5):237-240. doi: 10.1016/j.endinu.2017.03.006. Epub 2017 Apr 26.

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):435-437. doi: 10.1016/S2213-8587(17)30314-5. Epub 2017 Oct 10.

Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.

Nat Rev Nephrol. 2018 Feb;14(2):78-80. doi: 10.1038/nrneph.2017.182. Epub 2018 Jan 8.

Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus.

J Diabetes Complications. 2023 Dec;37(12):108630. doi: 10.1016/j.jdiacomp.2023.108630. Epub 2023 Oct 23.

EMPA-REG OUTCOME: The Nephrologist's Point of View.

Am J Cardiol. 2017 Jul 1;120(1S):S59-S67. doi: 10.1016/j.amjcard.2017.05.012. Epub 2017 May 30.

EMPA-REG OUTCOME: The Nephrologist's Point of View.

Am J Med. 2017 Jun;130(6S):S63-S72. doi: 10.1016/j.amjmed.2017.04.007. Epub 2017 May 16.

Introduction.

Am J Cardiol. 2017 Jul 1;120(1S):S1-S3. doi: 10.1016/j.amjcard.2017.05.008. Epub 2017 May 30.

Results from Cardiovascular Outcome Trials in Diabetes.

Endocrinol Nutr. 2016 Aug-Sep;63(7):317-9. doi: 10.1016/j.endonu.2016.04.001. Epub 2016 Jun 17.

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11.

[SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].

MMW Fortschr Med. 2015 Oct 22;157(18):86-7.

引用本文的文献

Type 2 diabetes mellitus: Isn't it time to update the terminology?

World J Diabetes. 2025 Sep 15;16(9):107517. doi: 10.4239/wjd.v16.i9.107517.

Diabetes in spotlight: current knowledge and perspectives of photobiomodulation utilization.

Front Endocrinol (Lausanne). 2024 Mar 19;15:1303638. doi: 10.3389/fendo.2024.1303638. eCollection 2024.

Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.

touchREV Endocrinol. 2021 Nov;17(2):92-101. doi: 10.17925/EE.2021.17.2.92. Epub 2021 Nov 17.